Related Experiment Video
Updated: Jul 31, 2025

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
NIVOLUMAB ASSOCIATED ENDOCRINE ABNORMALITIES: CHALLENGING CASES FROM A REFERENCE CLINIC
M C Unal1, G Güngör Semiz1, O Ozdoğan2
1Endocrinology and Metabolism, Dokuz Eylul University, Faculty of Medicine, Izmir, Turkey.
Immune checkpoint inhibitors (ICIs) can cause endocrine issues. Three patients developed fat loss, thyroiditis, or adrenal insufficiency after PD-1 therapy, highlighting the need for vigilance.
Area of Science:
- Oncology
- Endocrinology
- Immunology
Background:
- Immune checkpoint inhibitors (ICIs) represent a significant advancement in treating advanced cancers.
- Antibodies targeting programmed cell death receptor 1 (PD-1) restore anti-cancer immune responses.
More Related Videos
09:48An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
06:08Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023
Related Concept Videos
Treatment Resistant Cancers
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Tumor Immunotherapy
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...